Posted by Michael Wonder on 23 Jul 2019
Drug maker group boosts lobbying as push to lower prices stalls
23 July 2019 - Top companies also report higher spending in second quarter.
The drug industry’s primary trade group increased its spending on lobbying during the second quarter, as President Donald Trump’s promised efforts to lower the prices of prescription drugs stalled.
The Pharmaceutical Research and Manufacturers of America, which represents leading drug makers, reported spending $6.2 million in the quarter that ended June 30, a 12% increase from $5.5 million in the same period last year, according to a disclosure filed with Congress by Monday’s deadline. The group reported lobbying on several pieces of legislation that dealt with drug pricing.
